Babak Alex Vakili: Net Clinical Benefit Favors OAC Alone, According to the AQUATIC Trial
Babak Alex Vakili, President and CEO at Heart Vein and Vascular Clinic, shared on LinkedIn:
”For Atrial Fibrillation patients with CAD, who are > 6 months post PCI and who are on OAC (Eliquis, Xarelto) and Aspirin combination, stop aspirin unless strongly indicated (eg recent ACS or stent thrombosis). Net clinical benefit favors OAC alone, according the Aquatic Trial.
NEJM AQUATIC Trial (Oct 23 2025)
- Published in The New England Journal of Medicine
- Title: Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation
In this double-blind, multicenter French RCT (N = 872), patients with prior PCI and high atherothrombotic risk—all on long-term oral anticoagulation (OAC)—were randomized to OAC + aspirin 100 mg daily vs OAC + placebo.
After a median 2.2 years, the trial was stopped early due to excess deaths in the aspirin arm.
Results:
- Primary composite (CV death, MI, stroke, embolism, revasc, acute limb ischemia): 16.9 % with aspirin vs 12.1 % placebo → HR 1.53 (P = 0.02)
- All-cause death: 13.4 % vs 8.4 % → HR 1.72 (P = 0.01)
- Major bleeding (ISTH): 10.2 % vs 3.4 % → HR 3.35 (P < 0.001)
Oral anticoagulants used:
Apixaban ~60–62 %, Rivaroxaban ~25 %, Dabigatran ~3–5 %, Warfarin ~10 % (≈ 90 % DOACs overall).
Top 5 Takeaways:
- In CCS patients >6–12 mo post-PCI on OAC, adding aspirin increases ischemic events and bleeding without benefit.
- All-cause mortality was significantly higher with OAC + ASA.
- Major bleeding tripled with dual therapy.
- Apixaban was the most common OAC, mirroring real-world practice.
- OAC monotherapy should be the default after the initial post-PCI period unless clear indication for ASA exists.”
Article: Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation
Authors: Gilles Lemesle, Romain Didier, Philippe Gabriel Steg, Tabassome Simon, Gilles Montalescot, Nicolas Danchin, Christophe Bauters, Didier Blanchard, Claire Bouleti, Denis Angoulvant, Stéphane Andrieu, Gérald Vanzetto, Mathieu Kerneis, Véronique Decalf, Etienne Puymirat, Dominique Mottier, Abdourahmane Diallo, Eric Vicaut, Martine Gilard, Guillaume Cayla

Read full articcle here.
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 18, 2026, 14:13Alvin Katumba: Sickle Cell Disease Research Recognised With a 2026 ASH Abstract Achievement Award
-
Nov 18, 2026, 13:34Vincenzo De Angelis: Strengthening Plasma Management and Quality Control in Eastern Europe
-
Nov 18, 2026, 13:34Standardizing Bleeding Outcome Assessment in Hemophilia Clinical Trials – JTH
-
Nov 18, 2026, 13:34Nicolas Gendron: Towards Sustainable Anticoagulation
-
Nov 18, 2026, 13:33Breaking the Silence on Women and Girls with Bleeding Disorders – EHC
-
Nov 18, 2026, 13:32Maria Elisa Mancuso: Next-Generation Protein Therapies in Hemophilia
-
Nov 18, 2026, 13:25Maia Meier: Advocating for Women and Girls with Bleeding Disorders
-
Nov 18, 2026, 13:19Sjoerd Fabian Koopman: Exploring Tissue Distribution of Extended Half-Life Factor IX Concentrates
-
Nov 18, 2026, 13:16Ifeanyichukwu Ifechidere: Choosing Between Clot-Based and Chromogenic Coagulation Assays